These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 32642919

  • 21. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.
    Tang C, Chen P, Si FL, Lv JC, Shi SF, Zhou XJ, Liu LJ, Zhang H.
    Am J Kidney Dis; 2024 Aug; 84(2):170-178.e1. PubMed ID: 38364955
    [Abstract] [Full Text] [Related]

  • 22. Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.
    Okabayashi Y, Tsuboi N, Haruhara K, Kanzaki G, Koike K, Shimizu A, Miyazaki Y, Ohno I, Kawamura T, Ogura M, Yokoo T.
    Clin Exp Nephrol; 2016 Dec; 20(6):910-917. PubMed ID: 26830548
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of appropriate treatment for IgA nephropathy with mild proteinuria and normal renal function.
    Ogura S, Moriyama T, Miyabe Y, Karasawa K, Nitta K.
    Clin Exp Nephrol; 2021 Oct; 25(10):1103-1110. PubMed ID: 34101029
    [Abstract] [Full Text] [Related]

  • 24. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.
    Zhao YF, Zhu L, Liu LJ, Shi SF, Lv JC, Zhang H.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):947-955. PubMed ID: 27026518
    [Abstract] [Full Text] [Related]

  • 25. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
    Ismail G, Obrişcă B, Jurubiţă R, Andronesi A, Sorohan B, Vornicu A, Sinescu I, Hârza M.
    Medicine (Baltimore); 2020 Jun 26; 99(26):e21000. PubMed ID: 32590815
    [Abstract] [Full Text] [Related]

  • 26. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
    Yang X, Ma F, Bai M, Wang Y, Jia Q, Dong R, Liu C, Sun S.
    Ren Fail; 2021 Aug 10; 43(1):1180-1187. PubMed ID: 34376108
    [Abstract] [Full Text] [Related]

  • 27. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
    Wu H, Fang X, Xia Z, Gao C, Peng Y, Li X, Zhang P, Kuang Q, Wang R, Wang M.
    J Nephrol; 2020 Dec 10; 33(6):1263-1273. PubMed ID: 32507961
    [Abstract] [Full Text] [Related]

  • 28. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
    Yu MY, Kim YC, Koo HS, Chin HJ.
    PLoS One; 2017 Dec 10; 12(11):e0188375. PubMed ID: 29155873
    [Abstract] [Full Text] [Related]

  • 29. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 10; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 30. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
    Jia Q, Ma F, Yang X, Li L, Liu C, Sun R, Li R, Sun S.
    Clin Exp Nephrol; 2022 Mar 10; 26(3):257-265. PubMed ID: 34724588
    [Abstract] [Full Text] [Related]

  • 31. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 10; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 32. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.
    Pediatr Nephrol; 2017 Jan 10; 32(1):139-150. PubMed ID: 27557557
    [Abstract] [Full Text] [Related]

  • 33. Severity of nephrotic IgA nephropathy according to the Oxford classification.
    Moriyama T, Nakayama K, Iwasaki C, Ochi A, Tsuruta Y, Itabashi M, Tsukada M, Takei T, Uchida K, Nitta K.
    Int Urol Nephrol; 2012 Aug 10; 44(4):1177-84. PubMed ID: 22231129
    [Abstract] [Full Text] [Related]

  • 34. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
    Gong WY, Liu M, Luo D, Liu FN, Yin LH, Li YQ, Zhang J, Peng H.
    BMC Nephrol; 2019 Apr 30; 20(1):150. PubMed ID: 31039758
    [Abstract] [Full Text] [Related]

  • 35. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
    Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F.
    J Am Soc Nephrol; 2004 Jan 30; 15(1):157-63. PubMed ID: 14694168
    [Abstract] [Full Text] [Related]

  • 36. Comparison between patients with IgA nephropathy with minimal change disease and patients with minimal change disease.
    Li XW, Cheng SQ, Liang SS, Le WB, Zeng CH, Wang JQ, Liu ZH.
    Clin Nephrol; 2016 May 30; 85(5):273-81. PubMed ID: 26951969
    [Abstract] [Full Text] [Related]

  • 37. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study.
    Wang Z, Zhou X, Shi S, Liu L, Lv J, Zhang H.
    Am J Nephrol; 2024 May 30; 55(5):529-538. PubMed ID: 39074466
    [Abstract] [Full Text] [Related]

  • 38. Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.
    Sarcina C, Tinelli C, Ferrario F, Visciano B, Pani A, De Silvestri A, De Simone I, Del Vecchio L, Terraneo V, Furiani S, Santagostino G, Corghi E, Pozzi C.
    PLoS One; 2016 May 30; 11(7):e0158584. PubMed ID: 27416024
    [Abstract] [Full Text] [Related]

  • 39. Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study.
    Guo Y, Shi S, Zhao J, Wang C, Liu Z, Fu S, Chen N, Li G, Wang L, Ni Z, Zhang H, Lai L, Lv J, Zhang H.
    Ren Fail; 2024 Dec 30; 46(2):2398826. PubMed ID: 39248402
    [Abstract] [Full Text] [Related]

  • 40. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers.
    Choi S, Lee D, Jeong KH, Moon JY, Lee SH, Lee TW, Ihm CG.
    Clin Nephrol; 2009 Nov 30; 72(5):353-9. PubMed ID: 19863877
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.